Teon Therapeutics has treated the first subject in its Phase I/II clinical trial of TT-816 in patients with advanced solid tumours.

The first-in-human, open-label, multiple ascending dose and dose-expansion trial is assessing the safety and efficacy of TT-816 given orally.

The phase I portion is studying TT-816 monotherapy’s safety, tolerability, pharmacokinetics, and initial clinical activity, and will identify a recommended dose for Phase II.

Phase II will analyse the safety and define the initial efficacy of TT-816 monotherapy in combination with a PD-1 inhibitor in the advanced solid tumour settings including non-small cell lung cancer, ovarian cancer, and renal cell carcinoma.

In the trial, the company plans to enrol 200 subjects with advanced solid tumours who are unresponsive to the standard-of-care and may not have anymore therapy options.

An oral cannabinoid CB₂ receptor antagonist, TT-816 works as an immune checkpoint inhibitor to treat various solid tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to preclinical data, the therapy showed to boost NK cell tumour killing and T cell activation effects in vitro, enhancing tumour infiltrating T cells and NK cells in vivo.

Teon Therapeutics CEO Serge Messerlian said: “The initiation of our Phase I/II trial of TT-816 is an important step in our mission to invent new hope for patients by providing meaningful treatments to those with few remaining alternatives.

“Supported by strong preclinical data, we believe TT-816 has unique mechanisms of action that go beyond current checkpoint inhibitors by enhancing both T cell and NK cell antitumor immunity, preventing broad-based T cell exhaustion, synergising antitumor effects with current immune checkpoint inhibitor therapies, and directly promoting T cell infiltration into solid tumours.”